Zhuo Yue Labs

Back to Home

Investor Materials

Strategic Review and Transaction Terms

Public-facing investor materials focused on valuation ranges, transaction structures, and asset perimeter details prepared for investor, search-fund, family-office, and strategic-buyer evaluation.

Headline Transaction Terms

Illustrative investment and sale structures. Management is pursuing either (i) a minority growth-capital investment, (ii) a control or majority recapitalization, or (iii) a full all-assets sale. The preferred public positioning is flexible, with the minority path presented first and a full-scale asset transaction available for qualified strategic or financial buyers.

Transaction Overview

Transaction Item Headline Position
Seller / Counterparty Zhuo Yue Labs operating platform
Primary transaction paths Minority equity investment, control recapitalization, or all-assets sale
Inventory treatment Transfer at close; current landed value estimated at $40k–60k
Owned audience 1,300-contact mailing list and 750-member Discord community included in sale perimeter
Asset perimeter Brand, domains, storefront, codebase, customer data, SOPs, vendor relationships, inventory, and community assets

Minority Growth-Capital Structure

Minority Terms Headline
Pre-money valuation $1.80m
Capital raise size $200k–500k primary
Post-money valuation $2.00m–2.30m
Indicative stake sold 10.0%–21.7% post-money
Use of proceeds Inventory expansion, hiring, automation, marketing scale, and working capital
Governance Customary information rights; board structure negotiable

Control / Majority Recapitalization

Control Terms Headline
Implied equity value $2.00m
Available stake 51%–80%
Indicative purchase price $1.02m–1.60m
Structure Flexible mix of primary and secondary consideration
Founder transition Seller available for negotiated transition support

All-Assets Sale Structure

Asset Sale Terms Headline
Headline all-assets sale ask $1.35m excluding transferred inventory
Inventory at close Additional purchase price or closing adjustment based on $40k–60k landed value
Included assets Brand, domains, storefront, codebase, CRM/order history, mailing list, Discord, SOPs, vendor relationships
Target buyer profile Search fund, family office, strategic buyer, or sector competitor
Transition support Negotiable handover and post-close support period

Rationale for Valuation

The headline valuation frame reflects premium brand positioning, pricing power, systemized workflows, owned audience channels, developed digital infrastructure, vendor relationships, and a meaningful inventory base available for immediate turnover.

Valuation Context

Public-facing investor materials are limited to valuation framing, transaction structures, platform footprint, and asset perimeter context suitable for investor, search-fund, family-office, or strategic-buyer evaluation.

Executive Summary

Zhuo Yue Labs is a premium peptide e-commerce platform with a restrained institutional brand presentation, a high-trust website experience, owned audience channels, and a systemized operating workflow. Management is open to either minority growth capital or a full all-assets transaction, with flexibility around control structures where the right counterparty and execution plan are present.

Detailed internal revenue, expense, and operating disclosures are intentionally excluded from this public investor page and can be provided separately in diligence where appropriate.

Valuation Metrics

Valuation Metric Value
Pre-money valuation$1.80m
Capital raise size$200k–500k primary
Post-money valuation$2.00m–2.30m
Control / majority recap value$2.00m implied equity value
All-assets sale ask$1.35m excluding transferred inventory
Inventory on hand$40k–60k
Owned audience1,300 mailing-list contacts; 750 Discord members

Platform Footprint and Asset Perimeter

Beyond the headline transaction framing, the operating platform includes a premium brand identity, the storefront and codebase, customer infrastructure, owned audience channels, standard operating workflows, vendor relationships, and inventory available for immediate turnover at close.

Platform Component Current Position
Brand positioningPremium peptide brand with institutional visual presentation and high-trust UI
Owned audience1,300-contact mailing list and 750-member Discord community
Pricing profileManagement indicates pricing power relative to peer positioning
OperationsDocumented and systemized workflows in place
Scale prioritiesHiring, automation, deeper inventory, broader fulfillment capacity
InventoryEstimated landed value of $40k–60k on hand

Indicative Transaction Frame

Management is open to multiple transaction structures. Current headline positioning supports a minority growth-capital raise at a $1.80m pre-money valuation, a control or majority recapitalization at an implied equity value of $2.00m, or a full all-assets sale at $1.35m excluding transferred inventory. On-hand inventory would be transferred at close through a customary closing adjustment or a separately agreed inventory purchase schedule.

Transaction Path Valuation / Ask Check Size Stake / Consideration Notes
Minority Growth Capital $1.80m pre-money $200k–500k primary 10.0%–21.7% post-money Growth capital for scale, inventory, hiring, automation
Control / Majority Recap $2.00m implied equity value 51%–80% available $1.02m–1.60m purchase price Flexible secondary / primary mix
All-Asset Sale $1.35m base purchase price Inventory transferred at cost $1.39m–1.41m all-in at current inventory estimate Includes brand, domains, site, customer base, mailing list, Discord, SOPs and operating assets

Asset Schedule

Asset Status / Schedule
Brand + trade dressIncluded
Domains, storefront, codebase and integrationsIncluded
Customer order history and CRM databaseIncluded
Mailing list1,300 contacts
Discord community750 members
SOPs and documented operating workflowsIncluded
Vendor and fulfillment relationshipsIncluded
On-hand inventory$40k–60k estimated landed value

Supporting schedules are included in the accompanying transaction workbook.

Zhuo Yue Labs • Investor Materials • As of 23 March 2026 • For qualified strategic and financial counterparties